
    
      This study will follow patients with hemophilia A, who have received a single intravenous
      administration of SPK-8011 in any prior Spark-sponsored SPK-8011 study. Subjects will be
      followed for up to a total of 5 years post infusion (including the time on the dosing study).
    
  